Annovis Bio Inc. (NYSE: ANVS) announced a partnership with NeuroRPM to implement AI-powered digital biomarker technology in its ongoing Parkinson's disease study. The collaboration will deploy NeuroRPM's FDA-cleared platform to monitor movement data and symptoms in the company's open-label study testing buntanetap.

The ANVS-25002 study is currently enrolling participants across 25 sites in the United States for a 36-month trial. The study has enrolled 90 out of an estimated 500 patients. NeuroRPM's platform uses wearable sensors and AI analytics to measure bradykinesia, tremor, and dyskinesia in real-time.

"We are excited to collaborate with NeuroRPM and believe that data-driven insights generated from its platform will complement our existing data collection and strengthen the evidence-based monitoring of disease progression throughout the trial," said Cheng Fang, Senior Vice President of Research and Development at Annovis.

The digital platform provides medication tracking, schedule reminders, and passive data collection designed to minimize patient burden. Atila Omer, CEO of NeuroRPM, stated that continuous wearable monitoring enables objective measurement in real-world settings.

In addition to the digital biomarker technology, Annovis is implementing a biomarker test for misfolded phosphorylated alpha-synuclein through a minimally invasive skin procedure. The company reports the assay delivers diagnostic sensitivity and specificity greater than 90 percent.

NeuroRPM, headquartered in Washington D.C., holds FDA 510(k) clearance for its technology platform. The company's system collects motion data during daily activities to provide insight into symptom patterns and treatment response over time.

Following the study completion, participants may have the option to continue using NeuroRPM technology for clinical monitoring by prescription, according to the company's statement.